Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-31 @ 1:26 PM
Study NCT ID:
NCT07427394
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-23
First Post:
2026-02-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Estrogen receptor (ER)-positive | View |
| None | Human epidermal growth factor receptor 2 (HER2)-negative | View |
| None | Cyclin-Dependent Kinase (CDK) 4 inhibitors | View |
| None | Pharmacokinetics | View |
| None | Anti-tumor activity | View |
| None | Selective Estrogen Receptor Degrader (SERD) | View |
| None | Safety | View |
| None | Tolerability | View |